Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock,…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $2.05 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to…
Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in…
Iterum Therapeutics plc Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial…
Melinta Therapeutics, Inc. Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the SEC-registered offering of 24,640,000…
Ardelyx, Inc. $50 Million Public Offering
Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc…
Coherus BioSciences, Inc. $86.25 Million Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common…
AbbVie Inc. $3 Billion 364-Day Term Loan Credit Facility
Davis Polk advised the lenders in connection with a $3 billion 364-day term loan credit facility for AbbVie Inc. …